Next, we analyzed the influence of these four genes on the biochemical recurrence-free survival (BRFS) of PRAD patients receiving radiotherapy, using the “surv_cutpoint” function, and divided them into two groups based on the expression of ALDH1A3 (Figure 3D, Table S4). The gene discussed is ALDH1A3; the disease is prostate adenocarcinoma.